Antibody to assay: The key to consistent and reproducible immunoassay results

Generating robust data from low sample volumes without spending hours or days optimizing your assay is more important than ever. Immunoassay kits offer ease of use and convenience – but using a kit with the right antibodies is critical.

In this webinar, Dr. Andrew Ball, VP, Assay Development Platforms at Abcam will introduce Abcam’s SimpleStep ELISA® kit, a single-wash assay which generates data in 90 minutes, and FirePlex®, a multiplexed immunoassay designed for HTS workflows, both powered by our recombinant antibody technology. Dr Ball will also discuss the advantages of Abcam’s portfolio of recombinant monoclonal antibodies, the core of their immunoassays. These include exceptional sensitivity and specificity as well as the highest level of batch-to-batch consistency and unrivaled reproducibility.

Plus, explore Abcam’s extensive validation processes which ensure the use of optimized antibody pairs in their immunoassay kit development, and which provide you the flexibility to scale your assay or adapt to your platform of choice.

About Abcam

Abcam is a global innovator working together with life scientists to advance research and enable faster breakthroughs. Its award-winning products and innovations enable scientists to save time and valuable resources, ensuring reproducible and reliable results that progress scientific understanding.

Key learning objectives

  • Learn about Abcam’s recombinant antibody technology which ensures highly specific and sensitive antibodies
  • How Abcam validate our recombinant antibody pairs to deliver reproducible and consistent Immunoassays
  • The advantages of Abcam’s 90-minute, single-wash Simplestep ELISA, and HTS compatible multiplexed immunoassay, FirePlex
  • How to effectively scale your assays

Who should attend?

Scientists already exploring biomarker discovery and who want to learn more.

Certificate of attendance

All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes.

Speakers

Andrew J. Ball Ph.D
Andrew J. Ball Ph.D
VP, Assay Development Platforms<p>Abcam</p>
Dora Wells
Dora Wells
Clinical Content Editor, SelectScience

Links

Tags